Doctor-patient trust is key to unlocking AI's potential to improve healthcare in Australia, finds Philips' Future Health Index Report
Three in four (74%) Australian healthcare professionals report losing clinical time due to incomplete or inaccessible patient data, with one fifth of these (19%) losing over 45 minutes per shift, amounting to 23 full days lost per year.
Australians are less optimistic about AI in healthcare (43%) compared to their healthcare providers (85%), highlighting a critical trust gap.
SYDNEY, AUSTRALIA - Media OutReach Newswire - 6 August 2025 - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today released the Australian findings of its 10th edition of the Future Health Index 2025 report: Building trust in healthcare AI. For the first time, the report includes the perspectives of more than 1,000 Australian patients alongside their healthcare professionals, revealing a clear directive: Australians will embrace AI in healthcare, but only if it enhances, rather than replaces, the vital doctor-patient relationship.
Whilst patients and providers see the potential for AI to address major challenges such as care delays and staff burnout, they believe its primary role should be to empower clinicians, allowing for more meaningful, human-centric care.
"This 10th edition of the Future Health Index gives us the clearest picture yet of what Australians want for their healthcare: technology must serve the human connection", said Shehaan Fernando, interim Managing Director of Philips Australia and New Zealand. "For patients, building trust is as important as building technology. At Philips, we are committed to a human-centric vision for AI that empowers clinicians and strengthens the doctor-patient relationship that Australians value".
Patients welcome tech, but protect p ersonal relationships
The report uncovers a key tension in Australian attitudes towards technology. Whilst a majority (66%) of Australians welcome new technology if it improves the quality of their care, more than half (53%) express concern that it could lead to less direct interaction with their doctors.
This desire for human connection is amplified by Australia's long-standing reliance on GP services as the foundation of the healthcare system. The findings suggest patients see AI's ideal role as a powerful support tool that handles administrative tasks, streamlines data access, and ultimately frees up GPs to engage in more in-depth, meaningful consultations. In Australia, three in four healthcare professionals (74%) report losing clinical time due to incomplete or inaccessible patient data, with one fifth of these (19%) losing more than 45 minutes per shift – adding up to 23 full days lost per healthcare professional each year [1]. AI's ability to manage and streamline patient data holds the key to reclaiming this time, allowing healthcare professionals to dedicate more focus to direct patient care.
Doctors as trusted guides to AI
When it comes to navigating the complexities of AI, Australians place their trust in their healthcare professionals. 79% of Australians would be most comfortable receiving information about AI in their care from their doctor, surpassing news outlets (48%) and social media (31%). This underscores the indispensable role of clinicians in guiding public acceptance and integration of AI.
However, the report also notes that healthcare professionals themselves have questions, with 77% concerned or unclear about liability for AI errors. Australians are less optimistic about AI's benefits (43%) compared to their healthcare providers (84%), highlighting a critical trust gap.
"As clinicians, we see the incredible potential for AI to help us diagnose earlier and create more personalised treatment plans", said Dr Tim Bowles, Head of Department - HIVE (Health in a Virtual Environment), at East Metropolitan Health Service (EMHS) in Western Australia. "AI can empower us to spend less time on administration and more time with our patients, ensuring technology elevates, rather than diminishes, the human element of care".
Philips ' Commitment: Driving Human-Centred Innovation
Philips' expertise in virtual hospital services and clinical command centres aligns with EMHS's efforts to improve patient-centred care and proactively detect the risk of patient deterioration. This collaboration, featuring the HIVE program and the deployment of a Clinical Command Centre solution leveraging machine learning and predictive analytics, has demonstrated significant patient outcomes.
"By integrating AI into our clinical workflows, we've been able to detect patient deterioration earlier, intervene faster, and ultimately deliver safer, more effective care. AI has become a vital tool in supporting our clinicians and improving outcomes when and where it matters most."
— Adam Lloyd, Area Director Community & Virtual Care East Metropolitan Health Service
Data indicates the Clinical Command Centre has led to a 26% reduction in patient mortality [2], a 30% reduction in length of stay [3], and has helped 15% of patients be discharged home faster [4]. Furthermore, the program facilitated over 10,000 clinical interactions over a 12-month period, with 10% being for urgent or life-threatening reasons, and 64% of all interactions occurring after hours or on weekends. By integrating technology seamlessly into clinical workflows, Philips helps to augment the skills of healthcare professionals and improve patient care when it's needed most.
"Our long-term vision is to deliver responsible, human-centric AI that addresses the real-world challenges of patients and providers", said Shehaan Fernando, interim Managing Director of Philips Australia and New Zealand. "By partnering with the medical community, we can ensure that innovation builds trust, improves outcomes, and supports a future of providing better care for more people".
For more information, or to download the full FHI 2025 Australia report, visit www.philips.com/futurehealthindex-2025.
[1] FHI 2025 Australia report: Based on an eight-hour shift, working 250 days per year. This amounts to 187.50 hours lost per healthcare professional on average.
[2] Lilly CM, et al. A Multi-center Study of ICU Telemedicine Reengineering of Adult Critical Care. CHEST. 2014; 145(3): 500-7.
[3] Lilly CM, et al. Hospital Mortality, Length of Stay and Preventable Complications Among Critically Ill Patients Before and After Tele-ICU Reengineering of Critical Care Processes. JAMA. June 2011; 305(21) 2175-83.[5] Impact of an Intensive Care Unit Telemedicine Program on a Rural Health Care System. Zawada, et al. Postgrad Med J, 2009; 121(3):160-170.
[4] Impact of an Intensive Care Unit Telemedicine Program on a Rural Health Care System. Zawada, et al. Postgrad Med J, 2009; 121(3):160-170.
Hashtag: #Philips
The issuer is solely responsible for the content of this announcement.
Royal Philips
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2024 sales of EUR 18.2 billion and employs approximately 70,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
About the Future Health Index
The Future Health Index is commissioned by Philips. In its 10th edition, the Future Health Index 2025 investigates how innovative technologies, particularly AI, can empower healthcare professionals to deliver better care for more people. Two quantitative surveys were carried out among more than 1,900 healthcare professionals and more than 16,000 patients in 16 countries. The surveys were conducted from December 2024 to April 2025. For more information, or to download the full FHI 2025 Global Report, visit www.philips.com/futurehealthindex-2025.
Royal Philips
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Zawya
a day ago
- Zawya
Merck Foundation and Nigeria First Lady meet to Build Healthcare Capacity, Support girl education and Break Infertility Stigma in Nigeria
Merck Foundation ( the philanthropic arm of Merck KGaA Germany underscored their commitment to build healthcare capacity, support girl education and break infertility stigma in Nigeria during their high-level meeting with H.E. Senator OLUREMI TINUBU, CON, The First Lady of the Federal Republic of Nigeria. The discussion was led by Prof. Dr. Frank Stangenberg Haverkamp, Chairman of Merck Foundation BOT and Senator, Dr. Rasha Kelej, CEO of Merck Foundation. Senator Dr. Rasha Kelej expressed, 'It was a privilege to meet my dear sister H.E. Senator OLUREMI TINUBU, CON, The First Lady of the Federal Republic of Nigeria and officially appoint her to be the Ambassador of 'Merck Foundation More Than a Mother'. During our meeting, we discussed the beginning of our long-term partnership and underscored our commitment towards building healthcare capacity and transforming patient care landscape by providing scholarships for local Nigerian doctors in 42 critical and underserved specialties. We also discussed about addressing critical social and health issues in the country including breaking the infertility stigma and supporting girl education.' 'It gives me great pleasure to share that till today, 63 scholarships have been provided for doctors in Nigeria and affirm our commitment towards enhancing healthcare delivery by providing scholarships for local doctors in Nigeria.' Dr Rasha Kelej added. H.E. Senator OLUREMI TINUBU, CON, The First Lady of the Federal Republic of Nigeria and Ambassador of 'Merck Foundation More Than a Mother' expressed, 'It is a pleasure to welcome and meet the Chairman and CEO of Merck Foundation in our country. I am truly pleased to learn about their impactful and highly beneficial programs, particularly Educating Linda program to support girl education and scholarship program for advancing healthcare capacity. It is encouraging to know that Merck Foundation has provided 63 scholarships to our local doctors in critical medical specialties. I am fully committed to scaling up all their programs to benefit our people.' Prof. Dr. Frank Stangenberg Haverkamp, Chairman of Merck Foundation BOT shared, 'It was a great pleasure to meet H.E. Senator OLUREMI TINUBU, CON, The First Lady of the Federal Republic of Nigeria, and to reinforce our shared commitment to advancing healthcare capacity in Nigeria and across Africa. Our aim is to improve the overall health and wellbeing of people by building healthcare capacity across Africa, Asia and other developing countries. We are strongly committed to transforming patientcare landscape through our scholarships program. Till today, we have provided more than 2282 scholarships for young doctors from 53 countries in 44 critical and underserved specialties.' Merck Foundation has provided 63 scholarships for Nigerian doctors, out of which 8 scholarships have been provided for Fertility, Embryology, Sexual&Reproductive Medicine, Biotechnology of Human Assisted Reproduction and Embryology and Women's Health. Moreover, 38 scholarships have been provided for Diabetes, Preventative Cardiovascular Medicine, Cardiology, Endocrinology and Obesity&Weight Management. After completion of the course, these doctors will be able to establish diabetes or hypertension clinics in their Health Centre or Hospital with the aim to help prevent and manage the disease in their own communities. Additionally, 17 scholarships have been provided for other critical and underserved specialties like Oncology Research, Clinical Psychiatry, Dermatology in Clinical Practice, Pain Management, Respiratory Medicine, Care of the Older Person, Critical Care, Rheumatology, and more. Moreover, As a part of their 'Educating Linda' program, Merck Foundation has also sponsored the education of 20 high performing but underprivileged Nigerian schoolgirls. Merck Foundation has also conducted three edition of Online Health Media Training for the Nigerian journalists, to emphasize on the important role that media plays to influence society to create a cultural shift with the aim to address wide range of social and health issues such as: Breaking Infertility Stigma, Supporting Girl Education, Women Empowerment, Ending Child Marriage, Ending FGM, and/ or Stopping GBV at all levels; to underscore the importance of Empowering Girls and Women in Education and to understand the social and psychological impact of infertility stigma and other social issues like GBV, Child Marriage, FGM etc. over women and their families and communities. Moreover, to raise awareness of early detection and prevention of Diabetes and Hypertension. Merck Foundation in partnership with The First Lady of Nigeria has also launched their 8 important Merck Foundation Awards for Media, Musicians&Singers, Fashion Designers, Filmmakers, and students&new potential talents in these fields. 'I invite the young Nigerian talents to share their creative and inspiring work with us. We have celebrated many winners from Nigeria in the previous years and look forward to celebrating winners this year too,' concluded Senator Dr. Kelej. Details of the Awards: Merck Foundation Media Recognition Awards 'More Than a Mother' 2025: Media representatives and media students are invited to showcase their work to raise awareness about one or more of the following social issues: Breaking Infertility Stigma and Women Empowerment. Submission deadline: 30 th September 2025. Merck Foundation Fashion Awards 'More Than a Mother' 2025: All Fashion Students and Designers are invited to create and share designs to deliver strong and influential messages to raise awareness about one or more of the following social issues: Breaking Infertility Stigma and Women Empowerment. Submission deadline: 30 th September 2025. Merck Foundation Film Awards 'More Than a Mother' 2025: All Filmmakers, Students of Film Making Training Institutions, or Young Talents of Africa are invited to create and share a long or short FILMS, either drama, documentary, or docudrama to deliver strong and influential messages to address one or more of the following social issues: Breaking Infertility Stigma and Women Empowerment. Submission deadline: 30 th September 2025. Merck Foundation Song Awards 'More Than a Mother' 2025: All Singers and Musical Artists are invited to create and share a SONG with the aim to address one or more of the following social issues: Breaking Infertility Stigma and Women Empowerment. Submission deadline: 30 th September 2025. Merck Foundation Media Recognition Awards 'Diabetes&Hypertension' 2025: Media representatives are invited to showcase their work through strong and influential messages to promote a healthy lifestyle and raise awareness about the prevention and early detection of Diabetes and Hypertension. Submission deadline: 30 th October 2025. Merck Foundation Fashion Awards 'Diabetes&Hypertension' 2025: All Fashion Students and Designers are invited to create and share designs to deliver strong and influential messages to promote a healthy lifestyle and raise awareness about the prevention and early detection of Diabetes and Hypertension. Submission deadline: 30 th October 2025. Merck Foundation Film Awards 'Diabetes&Hypertension' 2025: All Filmmakers, Students of Film Making Training Institutions, or Young Talents of Africa are invited to create and share a long or short FILMS, either drama, documentary, or docudrama to deliver strong and influential messages to promote a healthy lifestyle, raise awareness about prevention and early detection of Diabetes and Hypertension. Submission deadline: 30 th October 2025. Merck Foundation Song Awards 'Diabetes&Hypertension' 2025: All Singers and Musical Artists are invited to create and share a SONG with the aim to promote a healthy lifestyle and raise awareness about the prevention and early detection of Diabetes and Hypertension. Submission deadline: 30 th October 2025. Entries for the above awards can be submitted to us at: submit@ For information on the awards, please visit our website: Distributed by APO Group on behalf of Merck Foundation. Contact: Mehak Handa Community Awareness Program Manager Phone: +91 9310087613/ +91 9319606669 Email: About Merck Foundation: The Merck Foundation, established in 2017, is the philanthropic arm of Merck KGaA Germany, aims to improve the health and wellbeing of people and advance their lives through science and technology. Our efforts are primarily focused on improving access to quality&equitable healthcare solutions in underserved communities, building healthcare&scientific research capacity, empowering girls in education and empowering people in STEM (Science, Technology, Engineering, and Mathematics) with a special focus on women and youth. All Merck Foundation press releases are distributed by e-mail at the same time they become available on the Merck Foundation Website. Please visit to read more. Follow the social media of Merck Foundation: Facebook ( X ( Instagram ( YouTube ( Threads ( and Flickr ( The Merck Foundation is dedicated to improving social and health outcomes for communities in need. While it collaborates with various partners, including governments to achieve its humanitarian goals, the foundation remains strictly neutral in political matters. It does not engage in or support any political activities, elections, or regimes, focusing solely on its mission to elevate humanity and enhance well-being while maintaining a strict non-political stance in all of its endeavors.


The National
a day ago
- The National
Daily pill helps patients lose 12 per cent of body weight in clinical tests
An experimental daily weight loss pill has helped some people shed 12.4 per cent of their body weight in a milestone trial. Development of weight loss drugs has become something of an arms race in health care, as manufacturers look to develop the most effective, affordable alternatives to existing products such as Ozempic, Wegovy, Zepbound and Mounjaro. The drugs work by mimicking a natural hormone in the body that regulates blood sugar and appetite. While those drugs are all injectable, Orforglipron developed by US pharmaceutical giant Eli Lilly comes in tablet form, making it a potential game-changer for patients. A trial of 3,127 patients who took a daily pill for 72 weeks saw an average weight loss per person of 12.3kg. While injectable obesity drugs are peptides designed to replicate the appetite-controlling GLP-1 hormone, Orforglipron is a small molecule pill that is easier to manufacture and package. In the latest study of overweight or obese adults with weight-related health issues, the greatest weight loss was recorded in those taking the highest 36 milligram dose of Orforglipron. However, significant weight loss was also recorded in those taking a lower dose of just 6mg, with patients shedding 7.6 per cent of their weight. None of those involved in the study had diabetes, a condition for which Ozempic was initially manufactured to treat. Full results from the Lilly-backed trial will be presented next month at a major European diabetes meeting. "Obesity is one of the most pressing global health challenges of our time, driving global chronic disease burden and impacting more than one billion people worldwide," said Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health. "With Orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments. "With these positive data in hand, we are now planning to submit Orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need." According to the Global Obesity Observatory, about 26 per cent of adult men in the UAE are obese, and 30 per cent of women, leading to multiple related health problems, from heart disease to cancer. Multiple health benefits Weight loss drugs are proving to have multiple health benefits, and have the potential to treat multiple chronic ailments that cost global health authorities billions of dollars to treat. Wegovy, a drug approved for weight loss in the UAE, has been proven to reduce the risk of major heart problems, while the injectable diabetes drug Mounjaro has also been shown to have heart protective qualities. Early research has shown Orforglipron also lowered markers of heart disease risk, including cholesterol, triglycerides and blood pressure, across all doses. The most common side effects reported by patients involved in the Eli Lilly study were mild-to-moderate gastrointestinal issues, such as nausea and vomiting in a third of patients on the higher dosage. Weight-loss drug markets are expected to be worth $150 billion by 2030. A high dose oral version of Wegovy is also under consideration by the US Food and Drug Administration. Its manufacturer, Novo Nordisk said a recent trial showed the drug helped overweight or obese adults lose 15 per cent of their body weight. Global impact of obesity drugs The meteoric rise of Copenhagen-based Novo Nordisk drugs Ozempic and Wegovy fuelled double-digit growth in Denmark's economy. Ripples of that success have been felt around the world. Restaurants in Dubai are tweaking menus to suit those on weight-loss jabs, serving smaller portions high in protein, while tailors are being pressed into action to reduce the size of well-worn clothes. Meanwhile in the US, recent shortages of GLP-1 medications prompted The Obesity Action Coalition and The Obesity Society to call for increased regulations around compounding, where generic drugs are replicated without FDA approval. Once shortages were resolved, campaign groups called for greater enforcement of federal regulations and to discontinue production of generic drugs. 'GLP-1 medications have made a transformative impact in the obesity care space,' said Joseph Nadglowski, president and chief executive of Obesity Action Coalition. "As these medicines continue to grow in popularity, regulatory action and enforcement is critically needed at the state and federal level to ensure that patients have access to safe, FDA-approved treatments.'


Zawya
2 days ago
- Zawya
INTERVIEW: Strong Q2 results underscore strategy shift to complex care
Burjeel Holdings, the ADX-listed super-specialty healthcare provider, reported strong second-quarter results with net profit more than doubling and revenue rising nearly 19 percent year-on-year, driven by higher patient volumes and continued expansion in specialty services. In an interview with Zawya Projects, CEO John Sunil said the second quarter performance validated the group's strategy of investing in complex care areas such as oncology, women's health, and surgical specialties. 'The second quarter was strong for us, both in terms of results and execution,' Sunil said. 'We saw strong momentum in complex care, particularly in oncology, women's health, and surgical specialties.' The healthcare group has been expanding its regional footprint with new specialty centres in Dubai, Sharjah, Al Ain, and Oman, along with strategic acquisitions such as the Advanced Care Oncology Centre and a major rehabilitation facility in Riyadh. Despite deploying 403 million UAE dirhams in capital investments in the first half of 2025, Burjeel maintained a stable balance sheet and a 47 percent dividend payout, reflecting strong cash flows. The company reaffirmed its mid-teens revenue growth guidance for FY2025, with UAE and Saudi operations expected to anchor growth, while expansion into emerging markets like Africa will follow an asset-light Operations and Maintenance (O&M) model. Excerpts from the interview: What drove the strong Q2 performance and margin gains? We recorded 19 percent revenue growth and more than doubled our net profit, which was driven by operating leverage and better optimisation of our asset base. We have been very intentional about building a performance-driven culture. Even with 143 new physicians on boarded over the past year, we managed to optimise personnel costs through better workforce planning and scheduling. In fact, overheads came down by seven percent compared to the previous quarter and over 13 percent compared to Q4 last year. These improvements in cost control, combined with the top-line growth, led to a significant improvement in EBITDA margins. What's the strategy behind your mental health and rehab platforms? We believe in building a truly integrated model of care. With Alkalma, we are building a comprehensive mental health platform that has already launched four centres across the UAE and Saudi Arabia. Demand has been robust and continues to grow across different age groups. Similarly, our PhysioTherabia network in Saudi Arabia has grown to over 30 centres, supported by long-term government contracts. These platforms allow us to offer preventive, supportive, and recovery-oriented services that reduce the burden on acute care systems and improve overall outcomes. With the AED 170 million acquisition of Medeor Hospital's Dubai building, how does asset ownership support Burjeel's long-term strategic and financial goals? Owning the Medeor Hospital building in Dubai was a strategic move. It eliminated a long-term lease, gave us full operational control, and converted a high-performing facility into a capital asset. That translates directly into financial flexibility and cost efficiency. This investment also reflects our long-term commitment to Dubai as a strategic market. Could you share insights into your capital allocation strategy? Our capital allocation is guided by impact and long-term value. We're not just adding facilities - we're scaling services that meet clear clinical needs and deliver returns. Whether expanding oncology care, launching the Trust Fertility platform, or extending access to primary care, each investment aligns with our core strategy. At the same time, we are maintaining financial discipline. Free cash flow conversion improved significantly, and our debt remains well within manageable levels. We are focused on ensuring that each new asset is launched efficiently and begins contributing at its full potential. Expansion is important, but we are equally focused on execution and cost discipline. What are your expectations for the rest of FY2025? We are optimistic about the rest of the year. Many of our newly launched assets are starting to scale up. As utilisation improves, we expect continued margin improvement. We continue to target mid-teens revenue growth for the full year, supported by ongoing expansion in the UAE and Saudi Arabia. Our priorities remain clear on enhancing efficiency, deepening our subspecialty platforms, and scaling services through our core network and partnerships - particularly in high-impact areas such as oncology, transplant, fertility, orthopedics, and neuroscience. It is important to remember that major investments in specialised care and technology take time to translate into full financial returns. But this quarter shows that our strategy is beginning to deliver real value. How do you balance shareholder returns with reinvestment needs? We are committed to delivering value to our shareholders while ensuring the business is well-positioned for long-term growth. The 47 percent payout ratio reflects that balance. It rewards shareholders and preserves the flexibility we need to keep investing in our platform. As we continue to scale, we are open to exploring alternative funding instruments such as Sukuk, provided they align with our financial and strategic goals. But we will remain measured in our approach and focused on ensuring any capital raised is used for initiatives that create sustainable value. With rising rates, pricing pressures, and tighter regulation across MENA, how is Burjeel navigating this challenging operating environment? We are navigating this environment by staying agile and focusing on efficiency. Our diverse portfolio, which includes facilities across the UAE, Saudi Arabia, and Oman, and our mix of public and private contracts, provides us with a degree of resilience. We are also making meaningful progress in digital transformation. With tools like Oracle EMR and AI-based diagnostics, we are gaining better visibility across the system and improving both clinical and operational performance. This helps us manage costs and also positions us well for outcome-based reimbursement models, which are becoming more important in this regulatory landscape. Amid macro headwinds and expansion, how confident are you in meeting your FY2025 growth target? Yes, we are confident in our growth target. The strong performance in the first half gives us a solid platform. With many new centres coming online and strong demand for complex care, we expect momentum to continue into the second half. The UAE remains our largest and most mature market, particularly in high-acuity specialties. A great example is Trust Fertility Centre, now the largest of its kind in the country. It broke even within six months, treated over 1,800 patients, and delivered outcomes above global benchmarks. This type of replicable, high-impact model supports both our growth ambitions and our commitment to clinical excellence. Saudi Arabia continues to be a key growth engine. We are scaling our PhysioTherabia network and preparing to launch day surgery platforms. In emerging markets like Africa, we are exploring opportunities strictly through asset-light, zero-capex Operations and Management (O&M) partnerships. This allows us to expand our presence efficiently, without balance sheet exposure, while capturing growth opportunities across the regions. (Reporting by SA Kader; Editing by Anoop Menon) (